JPMorgan Chase & Co. bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Free Report) in the third quarter, HoldingsChannel.com reports. The fund bought 10,726 shares of the company’s stock, valued at approximately $166,000.
Several other institutional investors also recently made changes to their positions in the stock. RA Capital Management L.P. bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $152,234,000. Franklin Resources Inc. bought a new stake in Artiva Biotherapeutics in the third quarter valued at $7,435,000. Geode Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at $4,774,000. Samsara BioCapital LLC bought a new position in shares of Artiva Biotherapeutics during the third quarter worth about $4,506,000. Finally, Wellington Management Group LLP acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth about $2,912,000.
Artiva Biotherapeutics Stock Down 5.9 %
Artiva Biotherapeutics stock opened at $5.08 on Friday. Artiva Biotherapeutics, Inc. has a 12-month low of $4.77 and a 12-month high of $17.31. The company has a 50 day moving average of $9.68.
Wall Street Analyst Weigh In
ARTV has been the subject of several recent analyst reports. HC Wainwright began coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $21.00.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Featured Stories
- Five stocks we like better than Artiva Biotherapeutics
- 3 Warren Buffett Stocks to Buy Now
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- What is the Nikkei 225 index?
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Conference Calls and Individual Investors
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Want to see what other hedge funds are holding ARTV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Free Report).
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.